Today, the U.S. Food and Drug Administration approved daraxonrasib (Rasonque), a groundbreaking new drug for pancreatic cancer that targets...
Several recent studies, including on presented at the AACR Conference on the Science of Cancer Health Disparities, have examined...
By Ross Uhrich, DMD, MBA, ARPA-H Program Manager for POSEIDON and NITRO programs, Health Science Futures Mission Office What...
This month, AACR's journals editors highlighted factors that may reduce pancreatic cancer risk, a new humanized mouse model, and...
Understanding pancreatic cancer’s strengths may provide clues to its weaknesses.
For World Cancer Research Day, AACR convened a panel of experts to discuss how they are helping to drive...
Researchers are exploring new combinations of therapy, disrupting iron accumulation, and turning tumors hot in attempts to make ovarian...
Recent advances in the genomics of childhood cancer may help inform potential causes and better treatment strategies.
Amidst an FDA investigation into secondary cancers after CAR T therapy, researchers show the risk is likely minimal.
Former Philadelphia Mayor Michael Nutter received a humanitarian award for his work as a prostate cancer advocate and dedication...
Researchers examined how the molecular features of Hodgkin lymphomas differ between young and older patients.